By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Advion BioServices today said that under a new, multi-year contract it will provide drug giant Eli Lilly with drug discovery bioanalytical services

In addition, it said that Lilly will transition its drug discovery bioanalytical capability to Advion BioServices, which is a subsidiary of Advion BioSciences. All Lilly employees impacted by the transfer will have the opportunity to join Advion.

Financial terms of the transaction were not disclosed.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.

The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.

Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.

In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.